Literature DB >> 28691927

Ubiquitination of tumor suppressor PML regulates prometastatic and immunosuppressive tumor microenvironment.

Ya-Ting Wang1,2, Jocelyn Chen1,2, Chou-Wei Chang1, Jayu Jen3,4, Tzu-Yu Huang1, Chun-Ming Chen1, Roger Shen5, Suh-Yuen Liang1, I-Cheng Cheng6, Shuenn-Chen Yang5, Wu-Wei Lai7, Kuang-Hung Cheng8, Tao-Shih Hsieh6, Ming-Zong Lai9, Hung-Chi Cheng3,10, Yi-Ching Wang3,4, Ruey-Hwa Chen1,2.   

Abstract

The tumor microenvironment plays an important role in tumor growth and metastasis. However, the mechanism by which tumor cells regulate the cell and non-cell constituents of surrounding stroma remains incompletely understood. Promyelocytic leukemia (PML) is a pleiotropic tumor suppressor, but its role in tumor microenvironment regulation is poorly characterized. PML is frequently downregulated in many cancer types, including lung cancer. Here, we identify a PML ubiquitination pathway that is mediated by WD repeat 4-containing cullin-RING ubiquitin ligase 4 (CRL4WDR4). Clinically, this PML degradation pathway is hyperactivated in lung cancer and correlates with poor prognosis. The WDR4/PML axis induces a set of cell-surface or secreted factors, including CD73, urokinase-type plasminogen activator receptor (uPAR), and serum amyloid A2 (SAA2), which elicit paracrine effects to stimulate migration, invasion, and metastasis in multiple lung cancer models. In xenograft and genetically engineered mouse models, the WDR4/PML axis elevates intratumoral Tregs and M2-like macrophages and reduces CD8+ T cells to promote lung tumor growth. These immunosuppressive effects were all reversed by CD73 blockade. Our study identifies WDR4 as an oncoprotein that negatively regulates PML via ubiquitination to promote lung cancer progression by fostering an immunosuppressive and prometastatic tumor microenvironment, suggesting the potential of immune-modulatory approaches for treating lung cancer with aberrant PML degradation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28691927      PMCID: PMC5531412          DOI: 10.1172/JCI89957

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  61 in total

1.  The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.

Authors:  Andrea Rabellino; Brandon Carter; Georgia Konstantinidou; Shwu-Yuan Wu; Alessandro Rimessi; Lauren A Byers; John V Heymach; Luc Girard; Cheng-Ming Chiang; Julie Teruya-Feldstein; Pier Paolo Scaglioni
Journal:  Cancer Res       Date:  2012-03-09       Impact factor: 12.701

2.  A family of diverse Cul4-Ddb1-interacting proteins includes Cdt2, which is required for S phase destruction of the replication factor Cdt1.

Authors:  Jianping Jin; Emily E Arias; Jing Chen; J Wade Harper; Johannes C Walter
Journal:  Mol Cell       Date:  2006-09-01       Impact factor: 17.970

Review 3.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

4.  Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

Authors:  Stefani Spranger; Riyue Bao; Thomas F Gajewski
Journal:  Nature       Date:  2015-05-11       Impact factor: 49.962

5.  Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer.

Authors:  Chi-Tai Yeh; Alexander T H Wu; Peter M-H Chang; Kuan-Yu Chen; Chia-Ning Yang; Shuenn-Chen Yang; Chao-Chi Ho; Chun-Chi Chen; Yu-Lun Kuo; Pei-Ying Lee; Yu-Wen Liu; Chueh-Chuan Yen; Michael Hsiao; Pei-Jung Lu; Jin-Mei Lai; Liang-Shun Wang; Chih-Hsiung Wu; Jeng-Fong Chiou; Pan-Chyr Yang; Chi-Ying F Huang
Journal:  Am J Respir Crit Care Med       Date:  2012-09-28       Impact factor: 21.405

6.  SCP phosphatases suppress renal cell carcinoma by stabilizing PML and inhibiting mTOR/HIF signaling.

Authors:  Yu-Ching Lin; Li-Ting Lu; Hsin-Yi Chen; Xueyan Duan; Xia Lin; Xin-Hua Feng; Ming-Jer Tang; Ruey-Hwa Chen
Journal:  Cancer Res       Date:  2014-10-07       Impact factor: 12.701

7.  KLHL39 suppresses colon cancer metastasis by blocking KLHL20-mediated PML and DAPK ubiquitination.

Authors:  H Y Chen; J Y Hu; T H Chen; Y C Lin; X Liu; M Y Lin; Y D Lang; Y Yen; R H Chen
Journal:  Oncogene       Date:  2015-01-26       Impact factor: 9.867

Review 8.  New insights into the role of PML in tumour suppression.

Authors:  P Salomoni; B J Ferguson; A H Wyllie; T Rich
Journal:  Cell Res       Date:  2008-06       Impact factor: 25.617

9.  Promyelocytic leukemia protein controls cell migration in response to hydrogen peroxide and insulin-like growth factor-1.

Authors:  Erin L Reineke; Yu Liu; Hung-Ying Kao
Journal:  J Biol Chem       Date:  2010-01-25       Impact factor: 5.157

10.  Implication of PMLIV in both intrinsic and innate immunity.

Authors:  Faten El Asmi; Mohamed Ali Maroui; Jacques Dutrieux; Danielle Blondel; Sébastien Nisole; Mounira K Chelbi-Alix
Journal:  PLoS Pathog       Date:  2014-02-27       Impact factor: 6.823

View more
  22 in total

1.  Suppression of autophagy during mitosis via CUL4-RING ubiquitin ligases-mediated WIPI2 polyubiquitination and proteasomal degradation.

Authors:  Guang Lu; Juan Yi; Andrea Gubas; Ya-Ting Wang; Yihua Wu; Yi Ren; Man Wu; Yin Shi; Chenxi Ouyang; Hayden Weng Siong Tan; Tianru Wang; Liming Wang; Nai-Di Yang; Shuo Deng; Dajing Xia; Ruey-Hwa Chen; Sharon A Tooze; Han-Ming Shen
Journal:  Autophagy       Date:  2019-03-30       Impact factor: 16.016

Review 2.  Ubiquitin Ligases in Cancer Immunotherapy - Balancing Antitumor and Autoimmunity.

Authors:  Yu Fujita; Roberto Tinoco; Yan Li; Daniela Senft; Ze'ev A Ronai
Journal:  Trends Mol Med       Date:  2019-03-18       Impact factor: 11.951

3.  PML degradation fosters an immunosuppressive and pro-metastatic tumor microenvironment.

Authors:  Ya-Ting Wang; Ruey-Hwa Chen
Journal:  Mol Cell Oncol       Date:  2017-08-24

4.  Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer.

Authors:  Jieqiong Liu; Ying Wang; Zhenluan Tian; Ying Lin; Hengyu Li; Zhaowen Zhu; Qiang Liu; Shicheng Su; Yinduo Zeng; Weijuan Jia; Yaping Yang; Shengqiang Xu; Herui Yao; Wen Jiang; Erwei Song
Journal:  Nat Commun       Date:  2022-05-31       Impact factor: 17.694

Review 5.  Roles of ubiquitination in the crosstalk between tumors and the tumor microenvironment (Review).

Authors:  Xiuzhen Zhang; Tong Meng; Shuaishuai Cui; Dongwu Liu; Qiuxiang Pang; Ping Wang
Journal:  Int J Oncol       Date:  2022-05-26       Impact factor: 5.884

6.  WD40 protein Wuho controls germline homeostasis via TRIM-NHL tumor suppressor Mei-p26 in Drosophila.

Authors:  Elham Rastegari; Kreeti Kajal; Boon-Shing Tan; Fu Huang; Ruey-Hwa Chen; Tao-Shieh Hsieh; Hwei-Jan Hsu
Journal:  Development       Date:  2020-01-15       Impact factor: 6.868

Review 7.  Modulation of the tumor microenvironment by natural agents: implications for cancer prevention and therapy.

Authors:  Haseeb Zubair; Mohammad Aslam Khan; Shashi Anand; Sanjeev Kumar Srivastava; Seema Singh; Ajay Pratap Singh
Journal:  Semin Cancer Biol       Date:  2020-05-26       Impact factor: 15.707

8.  Identification of a Two-Gene (PML-EPB41) Signature With Independent Prognostic Value in Osteosarcoma.

Authors:  Shengye Liu; Jiamei Liu; Xuechen Yu; Tao Shen; Qin Fu
Journal:  Front Oncol       Date:  2020-01-24       Impact factor: 6.244

Review 9.  The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.

Authors:  Ji Cheng; Jianping Guo; Brian J North; Kaixiong Tao; Pengbo Zhou; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-12-30       Impact factor: 10.680

10.  Oxidized low density lipoprotein receptor 1 promotes lung metastases of osteosarcomas through regulating the epithelial-mesenchymal transition.

Authors:  Long Jiang; Shanshan Jiang; Wenjie Zhou; Jia Huang; Yongbin Lin; Hao Long; Qingquan Luo
Journal:  J Transl Med       Date:  2019-11-12       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.